Ce produit n'est pas destiné à diagnostiquer, traiter, guérir ou prévenir toute maladie. Ces déclarations n'ont pas été évaluées par la Food and Drug Administration.
Ces informations sont fournies à titre éducatif uniquement et ne remplacent pas un avis médical professionnel, un diagnostic ou un traitement. Consultez toujours votre professionnel de santé avant d'utiliser des plantes, surtout si vous êtes enceinte, allaitez, prenez des médicaments ou avez une condition médicale.
BM
MetabolicVérifié
Bitter Melon Metabolic
Momordica charantia
Gestion de la glycémie dans la médecine traditionnelle tropicale à travers le monde
Cette fiche a été compilée à partir de résumés PubMed (NIH) avec l'assistance d'une IA. Chaque affirmation factuelle est citée par un article PubMed réel (voir la liste des sources). Elle n'a pas encore été révisée par un humain — confirmez auprès d'un professionnel de santé avant utilisation.
Compilé à partir de 30 articles PubMed · modèle : gemma4:31b
Résumé
Momordica charantia is a tropical vine used as a vegetable and medicinal herb, primarily recognized for its glucose-lowering effects in diabetes management [PMID:32951763, PMID:35408574].
Contexte
Momordica charantia, also known as bitter gourd, karela, or balsam pear, is a member of the Cucurbitaceae family cultivated in tropical and subtropical regions [PMID:31487939, PMID:35656300].
Usages traditionnels
It has been used in the traditional medicine of China, India, and Sri Lanka to treat various diseases, serving as a stomachic, laxative, anthelmintic, and for the treatment of diabetes and its complications [PMID:31487939, PMID:35656300].
Composés actifs
Bioactive components include charantin, polypeptide-p (p-insulin), vicine, triterpenoids (such as momordicine I), saponins, flavonoids, phenolic acids, alkaloids, and polysaccharides [PMID:16910221, PMID:30790347, PMID:39408847, PMID:28503051].
Mécanisme d'action
Hypoglycemic effects are achieved by increasing pancreatic insulin secretion, decreasing insulin resistance, increasing peripheral and skeletal muscle glucose utilization, and inhibiting intestinal glucose absorption [PMID:30790347, PMID:28474032]. Other mechanisms include antioxidant activity via scavenging reactive oxygen species (ROS) and modulating inflammatory pathways [PMID:40170075, PMID:39408847].
Preuves cliniques
Preuve BType 2 Diabetes Mellitus
Bitter melon extract significantly decreased average fasting glucose levels over 12 weeks, although HbA1c levels remained unchanged [PMID:32951763].
Preuve BDiabetes (Non-insulin-dependent)
Water-soluble extract of fruits significantly reduced blood glucose concentrations during a 50 g oral glucose tolerance test [PMID:6786635].
Preuve BPrediabetes
Supplementation for twelve weeks improves biomarkers of glucose homeostasis [PMID:40199408].
Sécurité et effets indésirables
Reported adverse effects include headaches, a favism-like syndrome, increases in alkaline phosphatase and gamma-glutamyltransferase levels in animals, and severe reactions such as convulsions and hypoglycemic coma in children [PMID:12625217].
Interactions médicamenteuses
Bitter melon may have additive effects when taken concurrently with other glucose-lowering agents [PMID:12625217].
Synthèse des preuves
There is moderate clinical evidence (RCTs) supporting the hypoglycemic effects of M. charantia in diabetic and prediabetic populations, while extensive preclinical data (reviews/animal studies) suggest broader anti-inflammatory and antioxidant properties.
Sources PubMed
1.PMID: 32951763 (2020) — Hypoglycemic efficacy and safety of Momordica charantia (bitter melon) in patients with type 2 diabetes mellitus. · Complementary therapies in medicine
2.PMID: 40170075 (2025) — Oral administration of Momordica charantia-derived extracellular vesicles alleviates ulcerative colitis through comprehensive renovation of the intestinal microenvironment. · Journal of nanobiotechnology
3.PMID: 31487939 (2019) — The Role of Momordica charantia in Resisting Obesity. · International journal of environmental research and public health
4.PMID: 35408574 (2022) — Bioactives of Momordica charantia as Potential Anti-Diabetic/Hypoglycemic Agents. · Molecules (Basel, Switzerland)
Aucune monographie gouvernementale directe n'est disponible pour cette plante. Le contenu ci-dessous est généré par IA et n'a pas été vérifié par rapport à une source gouvernementale faisant autorité. Utilisez les liens de recherche pour consulter les sources officielles avant de vous fier à ces informations.
— Momordica charantia L.-Diabetes-Related Bioactivities, Quality Control, and Safety Considerations.
· Frontiers in pharmacology
6.PMID: 12625217 (2003) — Bitter melon (Momordica charantia): a review of efficacy and safety. · American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
7.PMID: 40199408 (2025) — Bitter gourd (Momordica charantia L.) supplementation for twelve weeks improves biomarkers of glucose homeostasis in a prediabetic population. · Journal of ethnopharmacology
8.PMID: 16910221 (2006) — Bitter gourd (Momordica Charantia): A dietary approach to hyperglycemia. · Nutrition reviews
9.PMID: 30790347 (2019) — Possible molecular mechanisms of glucose-lowering activities of Momordica charantia (karela) in diabetes. · Journal of cellular biochemistry
10.PMID: 28503051 (2017) — An Update Review on the Anthelmintic Activity of Bitter Gourd, Momordica charantia. · Pharmacognosy reviews
11.PMID: 28474032 (2017) — Momordica charantia: a popular health-promoting vegetable with multifunctionality. · Food & function
12.PMID: 6786635 (1981) — Improvement in glucose tolerance due to Momordica charantia (karela). · British medical journal (Clinical research ed.)
13.PMID: 39408847 (2024) — Therapeutic Potential of Momordicine I from Momordica charantia: Cardiovascular Benefits and Mechanisms. · International journal of molecular sciences